Purchase Order 75N91018P00652
Award Date 8/24/18
Potential Completion Date 8/23/19
Potential Value $23K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- <p>The National Cancer Institute awarded a purchase order to Standard Biotools Inc., doing business as Fluidigm, valued at $16,020.00, on May 7, 2018. No set-aside category was used. Place of performance is Bethesda, Maryland. The order has an ultimate completion date of July 10, 2019 and carries firm fixed pricing.</p>
- <p>The National Cancer Institute awarded a purchase order to Standard Biotools Inc. (doing business as Fluidigm) for $13,104.90 on July 3, 2018, with an ultimate completion date of July 3, 2019. The order, issued on a firm fixed price basis with no set-aside, procures antibodies. Place of performance is Bethesda, Maryland.</p>
- <p>The National Cancer Institute awarded a purchase order to Standard Biotools Inc. (doing business as Fluidigm) on September 7, 2017, with a ceiling value of $6,088.50. The order carries no set-aside designation. Place of performance is Bethesda, Maryland. The ultimate completion date is October 9, 2017. Pricing is firm fixed price. The specific requirements are not detailed in the source material.</p>
- <p>The National Cancer Institute awarded a purchase order to Standard Biotools Inc. (doing business as Fluidigm) for biological and reagent material valued at $13,690.00 on March 5, 2021, with completion scheduled for July 7, 2021. No set-aside was applied. Performance takes place in South San Francisco, California. The order is a firm fixed-price procurement for direct-use biological and reagent materials.</p>
- <p>The National Cancer Institute issued a purchase order to Standard Biotools Inc. (doing business as Fluidigm) on March 24, 2021, with a ceiling value of $24,881.50 for staining services on formalin-fixed, paraffin-embedded (FFPE) tissue slides. Work is performed in Bethesda, Maryland, under firm fixed price terms with an ultimate completion date of April 30, 2021. No small business set-aside applies to this order.</p>
- The National Cancer Institute awarded a purchase order to Standard Biotools Inc. (doing business as Fluidigm) valued at $177,816 on September 24, 2021, for a laser capture microdissection system. The order was issued as a simplified acquisition without a set-aside to de-obligate expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a). Work is performed at Bethesda, Maryland. The order's ultimate completion date was October 22, 2021. The originating solicitation, posted...
- This is a firm fixed-price purchase order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Standard Biotools Inc., doing business as Fluidigm. The $24,480.00 contract is for laboratory testing services and does not have a small business set-aside designation. Fluidigm is a for-profit manufacturer of advanced scientific instruments, reagents, and associated products and services used in biomedical, environmental, and healthcare...
- This contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), a civilian federal agency. The contract, valued at $137,800.00, is for a "C1 SYSTEM STANDARD SERVICE PLAN" and was awarded to the prime contractor, Standard Biotools Inc., doing business as Fluidigm. The contract type is a Firm Fixed Price Purchase Order, with a period of performance through March 6, 2021. The contract does not have a small business set-aside...
- This is a $24,795 firm-fixed-price purchase order contract awarded by the National Cancer Institute to Standard Biotools Inc., doing business as Fluidigm, for laboratory testing services. The contract has an ultimate completion date of December 31, 2025 and was not set aside for small businesses. Fluidigm is a for-profit manufacturer of advanced scientific instruments, reagents, and associated products and services, with a robust history of federal contracting across various government...
- <p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Standard Biotools Inc. (doing business as Fluidigm) on September 16, 2019, with a ceiling value of $19,158.00. No set-aside was used. Performance is at Bethesda, Maryland. The order is firm fixed price. Ultimate completion is September 16, 2020.</p>
The National Cancer Institute awarded a purchase order to Standard Biotools Inc. (doing business as Fluidigm) valued at $23,348.60 on August 24, 2018, with ultimate completion on August 23, 2019. No set-aside was used. Performance occurs in Bethesda, Maryland. The order is a firm fixed price commercial purchase; specific requirements are not detailed in the award notice.
Generated 8/1/26, 10:32 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $23.3k | 8/23/18 |